Skip to main content
. 2020 Jan 17;20:16. doi: 10.1186/s12890-020-1052-y

Table 1.

Infection control strategies used

Pediatric-treating services (n = 38) Adult-treating services (n = 22) p-value ≤200 patients (n = 52) > 200 patients (n = 8) p-value
Implementation of CF-specific infection control policy, n (%) 37/38 (97%) 18/22 (82%) 0.23 47/50 (94%) 8/8 (100%) 1.00
Contact precautions
 During hospital admission: NA NA NA
  All people with CF, n (%) 6/19 (32%) 8/9 (89%) 0.013
  MRSA infection, n (%) 26/29 (90%) 16/16 (100%) 0.54
  MRO infection, n (%) 15/21 (71%) 11/12 (92%) 0.22
 During ambulatory care: NA NA NA
  All people with CF, n (%) 4/32 (13%) 4/18 (22%) 0.44
  MRSA infection, n (%) 13/32 (41%) 7/18 (39%) 0.90
  MRO infection, n (%) 9/26 (35%) 6/18 (33%) 0.93
  Patient mask wearing policy 24/37 (65%) 12/22 (55%) 0.43 29/51 (57%) 7/8 (88%) 0.13
 Use of face-masks (regardless of whether mask-policy implemented): 1.00 0.25
  Surgical mask, n (%) 22/30 (73%) 11/14 (79%) 27/37 (73%) 6/7 (86%)
  N95 mask, n (%) 2/30 (7%) 1/14 (7%) 2/37 (5%) 1/7 (14%)
  Combination of mask types/other mask types, n (%) 6/30 (20%) 2/14 (14%) 8/37 (22%) 0/7 (0%)
Segregation strategies
 Hospital rooms used: 0.69 0.21
  Single room with ensuite only^, n (%) 19/31 (61%) 10/18 (56%) 27/43 (63%) 2/6 (33%)
  Combination of room types, n (%) 12/31 (39%) 8/18 (44%) 16/43 (37%) 4/6 (67%)
 During ambulatory care: 0.51 0.38
  Segregated waiting areas, n (%) 28/35 (80%) 13/19 (68%) 36/46 (78%) 5/8 (63%)
  Communal waiting areas, n (%) 7/35 (20%) 6/19 (32%) 10/46 (22%) 3/8 (38%)

CF cystic fibrosis, MRO multi-drug resistant, MRSA methicillin-resistant Staphylococcus aureus; ^includes isolation rooms also (n = 1 response), NA not applicable